- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
New data demonstrates long-term efficacy of Ofev in IPF
30 September 2015 • Author: Victoria White
An interim analysis of the INPULSIS-ON extension trial has confirmed the efficacy and safety of Boehringer Ingelheim’s Ofev (nintedanib) previously observed in the INPULSIS trials.
The results confirm that Ofev has a long-term effect on slowing disease progression and a manageable side effect profile in patients with idiopathic pulmonary fibrosis (IPF). IPF is a progressive disease, requiring patients to be on long-term treatment, so the new data is important.
The INPULSIS-ON interim analysis showed that the change from baseline in forced vital capacity (FVC) at 48 weeks in patients continuing treatment with Ofev in the extension trial was comparable to what was observed in the 52 weeks INPULSIS trial. This provides further evidence that the beneficial effect of Ofev on slowing disease progression is maintained in the long-term.
Safety and efficacy data for Ofev “very reassuring”
“The safety and efficacy data presented for Ofev is very reassuring with regards to the long-term outcomes of treatment with Ofev and its effect on slowing disease progression,” said Professor Luca Richeldi, Professor of Respiratory Medicine at the University of Southampton, United Kingdom. “They add further weight to the growing body of evidence in support of Ofev as an effective and manageable treatment for IPF. When managing IPF it is important that physicians discuss with their patients what to expect from treatment and which treatment is right for them, to initiate this treatment early and then to ensure the patient stays on it as long as possible.”
Ofev is a small molecule tyrosine kinase inhibitor. The drug slows disease progression by reducing the annual rate of decline in lung function by 50% in a broad range of IPF patient types. This includes patients with early disease, limited radiographic fibrosis (no honeycombing) on high resolution computed tomography (HRCT) and those with emphysema.
Ofev has regulatory approval in the US, Europe, Canada, Japan and Switzerland.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics